Vise Technologies Inc. Purchases 96,548 Shares of Pfizer Inc. $PFE

Vise Technologies Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 44.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 314,153 shares of the biopharmaceutical company’s stock after purchasing an additional 96,548 shares during the quarter. Vise Technologies Inc.’s holdings in Pfizer were worth $7,565,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. OVERSEA CHINESE BANKING Corp Ltd grew its holdings in shares of Pfizer by 19.4% during the second quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 83,573 shares of the biopharmaceutical company’s stock valued at $2,014,000 after buying an additional 13,567 shares during the last quarter. Csenge Advisory Group lifted its position in Pfizer by 3.2% in the 2nd quarter. Csenge Advisory Group now owns 154,984 shares of the biopharmaceutical company’s stock valued at $3,732,000 after acquiring an additional 4,774 shares in the last quarter. NewEdge Wealth LLC increased its holdings in shares of Pfizer by 3.2% in the 2nd quarter. NewEdge Wealth LLC now owns 83,856 shares of the biopharmaceutical company’s stock worth $2,019,000 after purchasing an additional 2,619 shares in the last quarter. Essential Partners LLC raised its stake in shares of Pfizer by 130.6% in the second quarter. Essential Partners LLC now owns 10,101 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 5,720 shares during the last quarter. Finally, Empirical Asset Management LLC lifted its holdings in shares of Pfizer by 47.0% during the second quarter. Empirical Asset Management LLC now owns 13,097 shares of the biopharmaceutical company’s stock valued at $315,000 after purchasing an additional 4,189 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PFE shares. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wolfe Research restated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and cut their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. Finally, Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.28.

Pfizer Price Performance

NYSE PFE opened at $28.00 on Friday. The company has a 50-day moving average price of $25.30 and a 200-day moving average price of $26.25. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.